Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU

František Duška, Petr Waldauf, Milada Halačová, Václav Zvoníček, Jakub Bala, Martin Balík, Jan Beneš, Olga Klementová, Irena Kozáková, Viktor Kubricht, Anne Le Roy, Tomáš Vymazal, Veronika Řehořová, Vladimír Černý, Czech Anaesthesia Clinical Trials and Audit Network, František Duška, Petr Waldauf, Milada Halačová, Václav Zvoníček, Jakub Bala, Martin Balík, Jan Beneš, Olga Klementová, Irena Kozáková, Viktor Kubricht, Anne Le Roy, Tomáš Vymazal, Veronika Řehořová, Vladimír Černý, Czech Anaesthesia Clinical Trials and Audit Network

Abstract

Background: Novel coronavirus SARS-CoV-2 is known to be susceptible in vitro to exposure to hydroxychloroquine and its effect has been found to be potentiated by azithromycin. We hypothesise that early administration of hydroxychloroquine alone or in combination with azithromycin can prevent respiratory deterioration in patients admitted to intensive care due to rapidly progressive COVID-19 infection.

Methods: Design: Prospective, multi-centre, double-blind, randomised, controlled trial (RCT).

Participants: Adult (> 18 years) within 24 h of admission to the intensive care unit with proven or suspected COVID-19 infection, whether or not mechanically ventilated. Exclusion criteria include duration symptoms of febrile disease for ≥ 1 week, treatment limitations in place or moribund patients, allergy or intolerance of any study treatment, and pregnancy.

Interventions: Patients will be randomised in 1:1:1 ratio to receive Hydroxychloroquine 800 mg orally in two doses followed by 400 mg daily in two doses and azithromycin 500 mg orally in one dose followed by 250 mg in one dose for a total of 5 days (HC-A group) or hydroxychloroquine + placebo (HC group) or placebo + placebo (C-group) in addition to the best standard of care, which may evolve during the trial period but will not differ between groups. Primary outcome is the composite percentage of patients alive and not on end-of-life pathway who are free of mechanical ventilation at day 14.

Secondary outcomes: The percentage of patients who were prevented from needing intubation until day 14, ICU length of stay, and mortality (in hospital) at day 28 and 90.

Discussion: Although both investigational drugs are often administered off label to patients with severe COVID-19, at present, there is no data from RCTs on their safety and efficacy. In vitro and observational trial suggests their potential to limit viral replication and the damage to lungs as the most common reason for ICU admission. Therefore, patients most likely to benefit from the treatment are those with severe but early disease. This trial is designed and powered to investigate whether the treatment in this cohort of patients leads to improved clinical patient-centred outcomes, such as mechanical ventilation-free survival.

Trial registration: Clinical trials.gov: NCT04339816 (Registered on 9 April 2020, amended on 22 June 2020); Eudra CT number: 2020-001456-18 (Registered on 29 March 2020).

Keywords: Azithromycin; COVID-19; Hydroxychloroquine; Novel coronavirus; Respiratory failure; SARS-CoV-2.

Figures

Fig. 1
Fig. 1
Overview of study procedures. Follow-up can be performed over the phone in outpatients. Note: D/C, discharge from ICU; F-up, follow up; LFT, liver function tests; MV, mechanical ventilation; SOFA, Sequential Organ Failure Assessment. *Primary outcome = being alive and off MV at D14. **This includes pregnancy test if applicable

References

    1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020.
    1. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020:269–71.
    1. Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55(4):105932. 10.1016/j.ijantimicag.2020.105932.
    1. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020.
    1. Gautret P. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial. 10.1016/j.ijantimicag.2020.105949.
    1. Jansen TC, Kompanje EJO, Druml C, Menon DK, Wiedermann CJ, Bakker J. Deferred consent in emergency intensive care research: what if the patient dies early? Use the data or not? Intensive Care Med. 2007;33:894–900. doi: 10.1007/s00134-007-0580-8.
    1. WHO. Clinical management of severe acute respiratory infection when COVID-19 is suspected (v1.2). 2020;1–21. Available from: . Accessed 8 Apr 2020.
    1. Cheng VC, Edwards KM, Gandhi R, Muller WJ. Last updated April 11, 2020 at 10:58 AM EDT and posted online at . Please check website for most updated version of these guidelines. 2020. Accessed 8 Apr 2020.
    1. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020;46(5):854–87. 10.1007/s00134-020-06022-5.
    1. Herridge MS, Moss M, Hough CL, Hopkins RO, Rice TW, Bienvenu OJ, et al. Recovery and outcomes after the acute respiratory distress syndrome (ARDS) in patients and their family caregivers. Intensive Care Med. 2016;42:725–738. doi: 10.1007/s00134-016-4321-8.
    1. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. JAMA. 2020;323(16):1612–4. 10.1001/jama.2020.4326.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera